



Second Edition

# The **clinical** **Neuropsychiatry** of **Multiple** **Sclerosis**

**Anthony Feinstein**



CAMBRIDGE

Medicine

CAMBRIDGE

[www.cambridge.org/9780521852340](http://www.cambridge.org/9780521852340)

This page intentionally left blank

# The Clinical Neuropsychiatry of Multiple Sclerosis

---

Multiple sclerosis (MS) is the most common cause of neurological disability in young and middle-aged adults. This fully updated and revised new edition provides a detailed account of the many neuropsychiatric disorders associated with MS and is relevant to both the research and the clinical setting. Using the latest brain imaging findings and results from treatment trials, the symptoms, assessment, diagnosis and treatment of depression in MS are covered, as are psychosocial factors and the link between depression and magnetic resonance imaging abnormalities. Subsequent chapters focus on cognitive dysfunction in MS, including the natural history of cognitive change, the use of screening instruments and neuropsychological batteries, brain imaging correlations and management strategies. The book concludes with a survey of the behavioral benefits and risks associated with disease-modifying drugs. It will be valuable to all mental health professionals, neurologists and others caring for those affected by MS.

**Anthony Feinstein** is Professor of Psychiatry at the University of Toronto.

## Reviews of the First Edition

“This is a clinically oriented volume, which is well researched, written and edited . . . Feinstein should be congratulated for his effort in reviewing and bringing together what is known of the psychiatry of MS . . .”

*British Journal of Psychiatry*

“This readable book is both a comprehensive overview, to be read cover-to-cover, and a reference volume, to be consulted as appropriate . . . Feinstein deserves particular commendation for his strong pragmatic and clinical bias . . . All in all, I recommend this book to complement any MS library.”

*The International MS Journal*

This volume illustrates the refreshing advantage of a single-authored work, which avoids the redundancy, inconsistency of approach, and lack of balance of multiauthored works. It is a pleasure to read. I recommend it not only for the long list of those who manage MS patients but for general neurologists and residents in neurology and psychiatry as well.

*Annals of Neurology*

This is a useful, well-written book that would be of interest to anyone concerned about cognitive dysfunction and the utility of neurological illnesses in illuminating the relationships between brain and behavior.

*American Journal of Psychiatry*

**To my parents**

# The Clinical Neuropsychiatry of Multiple Sclerosis

Second edition

Anthony Feinstein

University of Toronto, Canada



**CAMBRIDGE**  
UNIVERSITY PRESS

CAMBRIDGE UNIVERSITY PRESS

Cambridge, New York, Melbourne, Madrid, Cape Town, Singapore, São Paulo

Cambridge University Press

The Edinburgh Building, Cambridge CB2 8RU, UK

Published in the United States of America by Cambridge University Press, New York

[www.cambridge.org](http://www.cambridge.org)

Information on this title: [www.cambridge.org/9780521852340](http://www.cambridge.org/9780521852340)

© Cambridge University Press 2007

This publication is in copyright. Subject to statutory exception and to the provision of relevant collective licensing agreements, no reproduction of any part may take place without the written permission of Cambridge University Press.

First published in print format 2007

ISBN-13 978-0-511-28523-3 eBook (Adobe Reader)

ISBN-10 0-511-28283-4 eBook (Adobe Reader)

ISBN-13 978-0-521-85234-0 hardback

ISBN-10 0-521-85234-X hardback

Cambridge University Press has no responsibility for the persistence or accuracy of urls for external or third-party internet websites referred to in this publication, and does not guarantee that any content on such websites is, or will remain, accurate or appropriate.

Every effort has been made in preparing this publication to provide accurate and up-to-date information which is in accord with accepted standards and practice at the time of publication. Although case histories are drawn from actual cases, every effort has been made to disguise the identities of the individuals involved. Nevertheless, the authors, editors and publishers can make no warranties that the information contained herein is totally free from error, not least because clinical standards are constantly changing through research and regulation. The authors, editors and publishers therefore disclaim all liability for direct or consequential damages resulting from the use of material contained in this publication. Readers are strongly advised to pay careful attention to information provided by the manufacturer of any drugs or equipment that they plan to use.

# Contents

<i>Acknowledgement</i>	<i>page</i> vi
<i>Foreword</i>	vii
by Giancarlo Comi	
1 Multiple sclerosis: diagnosis and definitions	1
2 Depression: prevalence, symptoms, diagnosis and clinical correlates	28
3 Depression: etiology and treatment	46
4 Multiple sclerosis, bipolar affective disorder and euphoria	66
5 Multiple sclerosis and pseudobulbar affect	82
6 Multiple sclerosis and psychosis	99
7 Cognitive impairment in multiple sclerosis	115
8 The natural history of cognitive change in multiple sclerosis	145
9 Cognitive impairment in multiple sclerosis: detection, management and significance	155
10 Neuroimaging correlates of cognitive dysfunction	178
11 Multiple sclerosis, disease-modifying treatments and behavioral change	214
12 Multiple sclerosis: a subcortical, white matter dementia?	232
<i>Color plates are located between pages 140 &amp; 141</i>	
<i>Index</i>	257

# **Acknowledgement**

I would like to thank Alison Baldock, who kindly provided the cover illustrations.

## Foreword

Among neurological disorders, multiple sclerosis has the unfortunate honor of being the most frequent cause of disability in young individuals. With the evolution of the disease, the brain is progressively deprived of sensory inputs and largely loses the ability to produce adequate responses. A combination of inflammation and degeneration causes progressive brain and spinal cord atrophy, which starts very early in the disease course and increases during the disease process. In addition, widespread damage takes place in the surviving gray and white matter. Not surprisingly, the disease often impacts on higher brain functions with neuropsychiatric manifestations. These processes are all admirably reviewed in this book and, for each cognitive and psychiatric disorder, the physiopathological theories are extensively and critically examined, making the book very useful not only for physicians, but also for researchers. The exceptional experience of Anthony Feinstein in this area, demonstrated by many key papers produced in the last decade, emerges clearly, page after page: the analysis of the literature is always combined with the “personal” view and a very useful summary of the main findings.

There are many reasons why neuropsychiatric disorders assume a key role in the management of multiple sclerosis patients: they occur early and affect about half of the patients; they are the most frequent cause of unemployment and a major determinant of a reduced quality of life; moreover, they negatively affect the ability of the patients to adhere to therapeutic protocols and to benefit from the most recent advances in both etiologic and somatic treatment.

This book should be read by all multiple sclerosis physicians because it can contribute to better care for many patients.

Professor Giancarlo Comi, M.D.  
Director of the Department of Neurology  
and Clinical Neurophysiology  
San Raffael Hospital, Milan, Italy



# Multiple sclerosis: diagnosis and definitions

Many a chapter, monograph and paper on multiple sclerosis (MS) begins with the observation that the disease is the most common cause of neurological disability in young and middle-aged adults. While the emphasis for much of the nineteenth and twentieth centuries was on the neurological manifestations of the disease, since the mid 1980s clinicians, researchers and patients have become more aware of the associated behavioral changes. A burgeoning literature devoted to the neuropsychiatry of MS attests to this new found interest, although those with knowledge of the medical history of MS may find themselves a little surprised why it took so long for this enthusiasm to re-ignite. Descriptions of altered mentation in MS patients long predate the man credited with naming, describing and making the condition known, the French behavioral neurologist Jean-Martin Charcot (Charcot, 1868; see also Murray, 2005).

One cannot describe the psychiatric and cognitive changes associated with MS without first referring to the neurology and pathology of the disorder. This chapter, therefore, begins with a summary of the pathogenesis, pathology, signs and symptoms, diagnosis and differential diagnosis of MS. With the book's emphasis on mentation, this introduction will by design be brief and those seeking more detailed explanations are encouraged to consult the many texts specifically devoted to these aspects. This chapter will, however, discuss in depth the research guidelines for diagnosing MS and furnish clear definitions for terms that apply directly to the disease. These points are important for they will clarify at the outset many descriptive terms that appear in the MS research literature and are used throughout this book. The chapter will conclude with a discussion on rating disability and how behavioral changes may affect this assessment.

## Epidemiology

In the UK, the lifetime risk for multiple sclerosis is 1:800, which translates into approximately 60 000 people with the disease (Compston, 1990). In the USA,

the figure is at least four times greater. There is a recognition that some cases of MS go undetected in life, appearing as a chance finding at postmortem (Gilbert and Sadler, 1983). Estimates that up to 20% of cases fall into this category (Mackay and Hirano, 1967) introduces a cautionary note in interpreting the epidemiological data. Generally, MS is seen with greater frequency as the distance from the equator increases in either hemisphere (Gonzalez-Scarano *et al.*, 1986; Skegg *et al.*, 1987). It is twice as common in women and, although it may occur at any age, the onset is typically in early adult life. The etiology is unknown and both genetic and environmental influences are considered important. The 31% monozygotic concordance rate, at six times the dizygotic rate (Sadovnik *et al.*, 1993), attests to the former, while evidence of environmental influences comes from three main sources. Migration studies have demonstrated that those who emigrate during childhood assume the risk of the country of adoption (Dean, 1967); disease epidemics have been reported in isolated communities such as the Faroe Islands (Kurtzke and Hyllested, 1979), and marked variations in prevalence have been found in genetically homogenous populations (Miller *et al.*, 1990).

## **Clinical features**

---

The disorder may present with diverse neurological signs that vary considerably between patients. Initial symptoms, which reflect the presence and distribution of the plaques, commonly involve numbness or tingling in the limbs or weakness affecting one or more limbs, loss of vision or impaired visual acuity, diplopia, facial numbness, vertigo, dysarthria, ataxia, urinary frequency or urgency and fatigue. Prominent cortical signs (i.e. aphasia, apraxia, recurrent seizures, visual field loss, early dementia and extrapyramidal symptoms such as chorea and rigidity) are unusual and seldom define the clinical presentation (Noseworthy *et al.*, 2000). The course of the disease is variable and initially difficult to predict. Approximately 5–10% of patients show a steady progression of disability from the onset of the disease. The remainder run a relapsing–remitting course of which 20–30% never become seriously disabled and continue to function productively 20–25 years after symptom onset (Sibley, 1990). However, the largest group (almost 60%) enter a phase of progressive deterioration a variable number of years after symptom onset. Even within this group, there is considerable variability, with a patient's condition fluctuating between relapses, periods of stability and progressive deterioration. Recent longitudinal outcome data from a study of 2837 MS patients paints a more optimistic picture than previously thought, with a median of 27.9 years elapsing before patients require a cane, at least, for walking (Tremlett *et al.*, 2006).

## Pathology

Although the exact pathogenesis of MS is uncertain, there is firm evidence of an autoimmune-mediated inflammatory disorder affecting the central nervous system (CNS) (Lisak, 1986; French-Constant, 1994). The target of the inflammatory response is myelin, a lipoprotein made by oligodendrocytes and investing the axons. Along the length of a nerve, the myelin sheaths are separated by gaps, the nodes of Ranvier. Nerve transmission is facilitated by impulses jumping from node to node in a process known as saltatory conduction. With damage to the myelin (i.e. demyelination), the conduction becomes impaired, transmission of nerve impulses is delayed or blocked completely and symptoms ensue.

Postmortem findings have further elucidated the neuropathological changes that occur (Allen, 1991). In patients severely affected by MS and who come to autopsy, the brain shows a mild degree of generalized atrophy with sulcal widening and dilatation of the ventricles. Plaques, which show histological evidence of demyelination, have a striking predilection for a bilateral periventricular distribution, particularly the lateral angles of the lateral ventricles, the floor of the aqueduct and the fourth ventricle. When viewed on sagittal section, the relationship of demyelination to the terminal veins may be seen. In some patients, the cerebrum is relatively spared, the main lesion load involving the optic nerves, brainstem and spinal cord (Allen, 1991). Cortical demyelination (Bruck and Stadelmann, 2005; Kutzelnigg and Lassmann, 2005; Merkler *et al.*, 2006) and cortical atrophy (Carone *et al.*, 2006; Prinster *et al.*, 2006) occur more often than previously thought, with the degree and type of pathological change correlating with the disease type. In a postmortem study of 52 MS patients of differing disease type (acute, relapsing–remitting, primary and secondary progressive; see p. 16), active and focal inflammatory demyelinating lesions in the white matter predominated in patients with acute and relapsing MS, whereas diffuse injury to white matter of normal appearance and cortical demyelination were characteristic of primary and secondary MS (Kutzelnigg *et al.*, 2005). The latter changes reflected diffuse axonal injury with an underlying global inflammatory response affecting the whole brain and meninges. Significantly, the relationship between the focal white matter lesion load on the one hand and diffuse white matter injury or cortical demyelination, on the other, was either weak or absent. These data point to a clear temporal sequence of pathological events: MS beginning as a focal inflammatory disease with circumscribed white matter plaques giving way over time to a chronic picture of diffuse inflammatory changes, slowly progressive axonal injury and cortical demyelination.

The conventional view of neuropathological changes can be briefly summarized as follows. In the early stages of myelin breakdown, oligodendrocytes are still

recognizable. As disease progresses, the myelin becomes progressively attenuated, partially detached from the axon and ultimately phagocytosed by invading macrophages. The early, established lesion shows a characteristic pattern of increased cells (macrophages, astrocytes), a mixture of intact and disintegrated myelin sheaths, perivascular inflammation (lymphocytes, plasma cells, macrophages), oligodendrocyte loss, relatively preserved axons and, within the gray matter, preservation of cell bodies. In non-acute but active plaques, there is hyperplasia of macrophages and astrocytes and lesions contain myelin lipid degradation products. Perivascular inflammation, although present, is sparse. While the edges of active lesions are hypercellular with evidence of normal and disintegrating myelin sheaths, the core of such lesions may resemble older, inactive plaques. As the lesion evolves from an active to non-active phase, signs of inflammation disappear. Chronic lesions, which generally make up the bulk of the large characteristic periventricular lesions seen in magnetic resonance imaging (MRI) or at postmortem, are, therefore, hypocellular, demyelinated, gliosed and contain few oligodendrocytes. The small venules are not inflamed, as in acute lesions, but rather show thickened hyalinized walls (Allen, 1991).

More recent data from actively demyelinating lesions, however, suggest a picture of greater complexity. Lucchinetti *et al.* (2000) examined biopsy and autopsy material with an array of immunological and biological markers and found marked lesion heterogeneity. Four different types of demyelination were noted based on the degree of myelin protein loss, the site and size of plaques, the patterns of oligodendrocyte destruction and the immunopathological evidence of complement activation. The four types of lesion (type I, macrophage-mediated demyelination; type II, antibody-mediated demyelination; type III, distal oligodendrogliopathy and apoptosis; and type IV, primary oligodendroglia degeneration) are thought to differ with respect to pathogenesis, as their descriptors indicate (Lucchinetti *et al.*, 2000; Lassmann *et al.*, 2001).

Advances in neuropathology have also challenged the historical view of MS as primarily a demyelinating disease in which axons are relatively spared. Using an antibody against amyloid precursor protein as a proven marker of axonal damage, Ferguson *et al.* (1997) examined paraffin-embedded MS lesions of varying ages. The results revealed the expression of amyloid precursor protein in damaged axons within acute MS lesions and in the active borders of less acute lesions. Confirmatory evidence of early axonal damage was soon provided by Trapp *et al.* (1998). Immunohistochemistry and confocal microscopy revealed that transected axons were a consistent feature in MS brain lesions, correlating with the degree of inflammation within a lesion. Thus, the greatest frequency of transected axons ( $11\,236/\text{mm}^3$ ) was found in active lesions, the density falling in the hypocellular edges of chronic active lesions ( $3138/\text{mm}^3$ ) and declining still further in the hypocellular center of chronic active lesions ( $875/\text{mm}^3$ ).

Irrespective of the stage of the lesion, remyelination may affect the changes observed. Remyelination has been noted in acute MS lesions (Prineas *et al.*, 1993), giving rise to thin myelin sheaths in areas previously noted to be free of myelin. Newly formed as opposed to surviving oligodendrocytes are thought to be the source (Prineas *et al.*, 1989). In chronic lesions where not all the myelin is lost, demyelination and remyelination are thought to be occurring simultaneously. In MS, remyelination is not complete, perhaps because repaired areas are subject to repeated bouts of demyelination, leading to either a reduction in oligodendrocyte precursors (termed O2A progenitor cells) or the creation of an environment that inhibits their migration (French-Constant, 1994).

Imaging studies during an acute attack have shown leakage of contrast-enhancing materials, indicative of a breakdown in the blood–brain barrier. The compromised barrier results in edema and the entry of immune mediators (antibodies and lymphocytes), which may contribute to myelin destruction. The leakage disappears spontaneously over 4–6 weeks (Miller *et al.*, 1988) and may be reversed temporarily by the administration of corticosteroids (Barkhof *et al.*, 1991). Postmortem studies have confirmed that lesions visualized by MRI and axial computed tomography (CT) correspond to MS plaques (Ormerod *et al.*, 1987). Furthermore, an *in vivo* study of MRI and histological parameters from six biopsy-proven cases of inflammatory demyelination of the CNS has shown that changes observed on MRI correlated with the evolving pattern of lesions (i.e. from acute to less active to chronic; Bruck *et al.*, 1997).

An important observation is that white matter that appears normal to the naked eye will more often than not show histological abnormalities. These include microscopic foci of demyelination; diffuse gliosis; perivascular inflammation; deposits of iron, lipofuscin and calcium; collagenization of small vessels; and axonal loss. Furthermore, this evidence of a more diffuse pathological process may occur in the absence of significant plaque formation. The clinical significance of these findings is that neuroimaging of the brain and spinal cord with standard sequences devised for plaque detection may mislead the observer into thinking the normal appearing white matter was indeed normal. Alternative imaging procedures for probing these more subtle changes have been devised, namely magnetic resonance spectroscopy, diffusion tensor and magnetization transfer imaging.

## **Diagnosis**

---

The diagnosis of MS carries major implications for patients and their families. Uncertainty over the future, the ability to work, earn a living and live independently are all issues that readily come to mind. It is, therefore, imperative for the clinician to be clear about what symptoms and signs constitute a diagnosis

of MS. In addition, making an early, correct diagnosis has assumed added importance because, for the first time, the MS patient is facing a choice of treatment options.

The diagnosis of MS can be made on clinical grounds alone. This requires that a patient have at least two episodes of neurological disturbance implicating different sites in the central white matter. A number of investigations may help the clinician to establish the presence and site of white matter lesions, thereby facilitating a diagnosis. It is, however, important to realise that these investigations (neuroimaging, evoked potentials and cerebrospinal fluid [CSF] electrophoresis) are not specific for MS and should be viewed only as helpful adjuncts to the clinical presentation.

From a research perspective, correctly diagnosing MS is equally important. The need for researchers across sites to talk the same language has prompted serial attempts to develop a set of diagnostic guidelines. For many years those of Schumacher *et al.* (1965) sufficed, but in response to improved laboratory and clinical procedures these gave way to the Poser criteria (Poser *et al.*, 1983).

### **The Poser Committee's recommendations**

---

The Poser Committee convened in Washington, DC in 1982 and comprehensively reviewed historical and clinical symptomatology in MS; immunological observations; CSF tests; a variety of neurophysiological, psychophysiological and neuropsychological procedures; neuroimaging procedures (CT and MRI); and urological studies of bladder, bowel and sexual function. They concluded that revisions to existing criteria were essential in order to conduct multicenter therapeutic trials, to compare epidemiological data, to evaluate new diagnostic procedures and to estimate disease activity (Poser *et al.*, 1983; Poser, 1984).

>Definitions and guidelines were provided for what constituted an MS attack (synonyms here included bout, episode, exacerbation, relapse), a remission, *clinical* evidence of a lesion, what constituted separate lesions, *paraclinical* evidence of a lesion (i.e. abnormalities on evoked potentials [Fig. 1.1], MRI [Fig. 1.2] and urological assessment) and *laboratory* support indicative of MS (i.e. increased production of immunoglobulin G (IgG) and the presence of CSF oligoclonal bands in the absence of such bands in the serum [Fig. 1.3]). The authors made it clear that MRI and evoked potential abnormalities were not considered *laboratory* evidence, but rather an extension of the *clinical* examination, hence the *paraclinical* label. Bringing together all these strands of evidence enabled the neurologist to arrive at one of four possible diagnoses: clinically definite MS, laboratory supported definite MS, clinically probable MS and laboratory supported probable MS. Of note was the committee's view that neuropsychological evidence of impaired




Fig. 1.1. Visual evoked potentials in a 33-year-old female with multiple sclerosis. Note the mildly delayed conduction in the right optic nerve (top) compared with left nerve (bottom); this is comparable with optic neuritis.

cognition in someone under 50 years, although suggestive of MS, was not specific enough to be considered diagnostic.<sup>1</sup>

In concluding, the committee acknowledged that there would always be patients who defied easy categorization. The experienced neurologist would have to rely on intuition and accumulated clinical skill in arriving at diagnoses for this group. The criteria outlined were primarily for research purposes. Furthermore, there was a recommendation that clinical trials and research protocols should be limited to patients in one of the two *definite* groups. The category of *probable* was designed for the purpose of prospectively evaluating new diagnostic methods. The Poser criteria would hold sway over the MS world for the next 18 years.

## The McDonald Committee's recommendations

In 2000, the International Panel on the Diagnosis of MS was convened with the aim of setting out new diagnostic criteria to be used by clinicians and adapted, as necessary,

<sup>1</sup> This recommendation, which was made in 1983, predated the plethora of studies from later in the decade that unequivocally demonstrated the presence of clinically significant cognitive dysfunction in approximately 40% of community based MS patients (Rao *et al.*, 1991, McIntosh-Michaelis *et al.*, 1991).




Fig. 1.2. Axial  $T_2$ -weighted (spin echo) scan demonstrating the extensive white matter lesions (multiple sclerosis plaques) in a typical periventricular distribution.




Fig. 1.3. Abnormal oligoclonal banding in patients 2 and 5, who both have a diagnosis of multiple sclerosis.

for clinical trials (McDonald *et al.*, 2001). Much had changed since the formulation of the Poser criteria, including significant advances in MRI technology, the advent of disease-modifying treatments such as the interferons beta-1a and beta-1b, and the recognition of a new disease course, namely primary progressive (see below).

The committee kept certain sacrosanct principles intact, namely that obtaining objective evidence of dissemination of lesions (typical of MS) in time and place was essential in making a secure diagnosis. Furthermore, while history taking was clearly informative, clinical evidence depended essentially on objectively determined neurological signs. A diagnosis of MS based purely on clinical grounds would, therefore, depend on objective evidence of lesions separated in time and space. Radiological and laboratory investigations retained their utility in the diagnostic process, but with some further caveats; For example, visual evoked potentials were still considered helpful but not somatosensory and brainstem readings, which were thought to contribute little to the diagnosis. Following a diagnostic evaluation, an individual was either deemed to have, or not to have, multiple sclerosis. While a category of *possible MS* was thought necessary (referring to a patient whose evaluation met some, but not all, of the necessary criteria), diagnostic categories such as clinically definite and laboratory supported MS were considered obsolete.

## **Definitions**

Definitions from previous diagnostic criteria were reviewed and where needed refined and clarified.

### **Attack (exacerbation, relapse)**

An attack referred to an episode of neurological disturbance (a subjective report *and* objective evidence) lasting at least 24 hours and not to be confused with a pseudo-attack, as might be caused by infection or change in core body temperature.

### **Time between attacks**

In defining what constituted separate attacks, it was felt that a minimum of 30 days should separate the onset of the first event from the onset of the second.

### **Paraclinical abnormalities: what are they?**

When Poser and his committee set out their criteria in 1982, MRI technology was in its infancy. Two decades later, the technique had substantially evolved and, given its pivotal role in assessing patients with MS, considerable attention was devoted to it by McDonald *et al.* (2001). A more detailed account of MRI abnormalities in MS appears in Chapter 10. Here it is sufficient to note that the McDonald criteria emphasised that MRI can provide evidence of dissemination of lesions in both time and space. A stringent procedure was adopted for

determining that MRI abnormalities were indicative of MS (Barkhof *et al.*, 1997; Tintoré *et al.*, 2000).

In keeping with the removal of the laboratory supported diagnostic label, the McDonald criteria incorporated CSF abnormalities under the paraclinical rubric. Analysis of CSF assumes greater importance if imaging results are equivocal or when the clinical presentation is atypical, but information from CSF cannot provide evidence of dissemination in time. As with the Poser definition, CSF significance pertains to the presence of oligoclonal IgG bands (distinct from such bands in the serum) and/or the presence of an elevated IgG index. Lymphocyte pleocytosis should be less than 50/mm<sup>3</sup>.

Abnormal visual evoked potentials typical of MS (delayed but with well-preserved waveform) remained a useful adjunct to the clinical examination and could provide evidence of a second lesion providing that the sole clinical manifestation was not limited to the visual pathways.

### **The McDonald classification criteria revised**

Four years after their publication, the McDonald criteria were revised (Polman *et al.*, 2005). New guidelines were provided to define what is meant by the dissemination of lesions in time, to clarify the significance of spinal cord lesions and to simplify the diagnosis of primary progressive MS. In the introduction to the revisions, the authors emphasised that the primary aim of the McDonald criteria was to help clinicians to make a valid and reliable diagnosis. This focussed on balancing the importance of arriving at an early, correct diagnosis with the need to avoid a false-positive diagnosis.

The committee acknowledged that the McDonald criteria had been derived from data largely pertaining to an adult Caucasian population. Therefore, the results from ongoing studies in Asian and South American groups were needed to validate the criteria more widely. Similarly, the applicability of the criteria to children was also questioned, with further work needed here. As with their predecessors, the committee made reference to the challenges posed by diseases that could mimic MS and the uncertainty over how best to classify disorders such as acute disseminated encephalomyelitis and neuromyelitis optica.

Give the central importance of these refined recommendations to any discussion of multiple sclerosis, the salient points are given here in greater detail.

### **Magnetic resonance imaging criteria to demonstrate brain abnormality and dissemination in space**

Three of the following are required.

1. At least one contrast (gadolinium)-enhancing lesion or nine  $T_2$  hyperintense lesions if there is no contrast-enhancing lesion.
2. At least one infratentorial lesion.

3. At least one juxtacortical lesion (i.e. involving the subcortical U fibres)
4. At least three periventricular lesions.

A spinal cord lesion was considered equivalent to a brain, infratentorial lesion; a contrast-enhancing spinal cord lesion was considered equivalent to a brain contrast-enhancing lesion and individual spinal cord lesions could be added to the overall count of lesions to meet the threshold count of nine lesions.<sup>2</sup>

Lesions should ordinarily be more than 3 mm in cross-section.

#### Magnetic resonance imaging criteria to demonstrate dissemination of lesions in time

This can be done in two ways.

1. Detection of a contrast-enhanced lesion at least three months after the onset of the initial clinical event, if not at the site corresponding to the initial event.
2. Detection of a *new*  $T_2$  lesion if it appears at any time compared with a reference scan done at least 30 days after the onset of the initial clinical event.

#### Diagnosis of multiple sclerosis in disease with progression from onset

The revised criteria are as follows.

1. One year of disease progression (retrospectively or prospectively determined).
2. Plus two of the following:
  - positive brain MRI (nine  $T_2$  lesions or four or more  $T_2$  lesions with positive visual evoked potentials)
  - positive spinal cord MRI (two focal  $T_2$  lesions)
  - positive CSF (iso-electric focussing evidence of oligoclonal immunoglobulin G (IgG) bands or increased IgG index, or both).

These guidelines have been incorporated into the full diagnostic criteria, which appear in Table 1.1.

#### The 2005 McDonald criteria revised for multiple sclerosis

To summarize, the revised McDonald criteria for MS (Table 1.1) retained the emphasis on objective clinical findings, repeated the importance for evidence of dissemination of lesions in time and space and clarified the use of confirmatory paraclinical examination to reduce the likelihood of false-positive and false-negative diagnoses (with a focus on specificity rather than sensitivity). In the authors' opinion, the revisions to the original McDonald MRI and CSF criteria, in particular, were of major import and the prediction was that they would have a matching effect on clinical practice.

<sup>2</sup> The reader is directed to Polman *et al.* (2005) for a more detailed account of what constitutes MS-related spinal cord pathology.

**Table 1.1.** The full diagnostic criteria of the revised McDonald classification

Clinical presentation	Additional data needed for MS diagnosis
Two or more attacks; objective evidence of two or more lesions	None
Two or more attacks; objective clinical evidence of one lesion	Dissemination in space, demonstrated by MRI; <i>or</i> two or more MRI-detected lesions consistent with MS plus positive CSF; <i>or</i> await further clinical attack implicating a different site
One attack; objective clinical evidence of two or more lesions	Dissemination in time, demonstrated by MRI <i>or</i> second clinical attack
One attack; objective clinical evidence of one lesion (monosymptomatic presentation; clinically isolated syndrome)	Dissemination in space, demonstrated by MRI <i>or</i> two or more MRI-detected lesions consistent with MS plus positive CSF; <i>and</i> dissemination in time demonstrated by MRI <i>or</i> second clinical attack
Insidious neurological progression suggestive of MS	One year of disease progression (retrospectively <i>or</i> prospectively determined) <i>and</i> two of the following demonstrations of dissemination in space: <ul style="list-style-type: none"> <li>(a) positive brain MRI (nine <math>T_2</math> lesions or four or more <math>T_2</math> lesions with positive visual evoked potential)</li> <li>(b) positive spinal cord MRI (two focal <math>T_2</math> lesions)</li> <li>(c) positive CSF</li> </ul>

*Note:* See Polman *et al.* (2005) for more complete details.

## Comparisons between the Poser and McDonald criteria

Comparisons between the Poser and McDonald (pre-revisions) criteria have been undertaken. In a study of 76 patients whose clinical features suggested a new diagnosis of MS, 38% were classified as clinically definite and 46% as laboratory definite MS according to the Poser system whereas 52% were diagnosed with MS by the McDonald criteria with the remaining 48% having 'possible MS' (Fangerau *et al.*, 2004). All patients with clinically definite MS were also diagnosed with MS by the McDonald method, but the same could only be said of 4 out of 35 patients with laboratory supported MS. Overall, using the McDonald criteria led to more diagnoses of MS than Poser's clinically definite criteria. However, when the

numbers were combined from Poser's clinically and laboratory definite categories, they exceed those diagnosed with MS by the McDonald system.

A second study assessed the two methods in a heterogeneous sample of 41 MS patients (15 relapsing–remitting, two secondary progressive, five primary progressive and 19 clinically isolated syndromes) and three non-MS cases (Zipoli *et al.*, 2003). Four neurologists were asked to make diagnoses according to both sets of criteria. Moderate inter-rater reliabilities were noted for both methods with respect to overall diagnosis ( $\kappa$  values of 0.52 and 0.57 for the McDonald and Poser criteria, respectively). A similar picture emerged for each system when it came to inter-rater agreements for distinct diagnostic categories. Finally, to assess possible sources of diagnostic disagreement, each rater was asked to assess specific factors such as dissemination over time and space, based on clinical and paraclinical (i.e. MRI) information only. Results revealed that, clinically, agreement for dissemination over time ( $\kappa = 0.69$ ) exceeded that for space ( $\kappa = 0.46$ ), whereas when it came to MRI analyses, the figures reversed ( $\kappa = 0.74$  and  $\kappa = 0.25$  for space and time respectively).

## **Clinically isolated syndromes**

Patients with clinically isolated syndromes (CIS) are of particular interest as they are frequently the forerunner of MS. In attempting to describe the natural history of psychiatric and cognitive abnormalities in MS, the study of such patients affords a valuable opportunity to document the earliest evidence of neurological dysfunction before patients progress to the full syndrome. Throughout the book, reference will be made to patients with CIS and a brief description of these conditions is, therefore, given here.

### **Optic neuritis**

Acute unilateral optic neuritis in adults is the presenting feature of MS in 20% of cases. It is characterized by the rapid development of visual loss, usually accompanied by pain, with symptoms progressing for 3–4 weeks and then resolving over 2–3 months, recovery to 6/9 vision occurring in greater than 90% of patients (McDonald, 1983). MRI with contrast enhancement may reveal lesions within the optic nerves (Fig. 1.4). In addition, two thirds of adults presenting with clinically isolated optic neuritis display one or more asymptomatic white matter brain lesions on MRI that appear indistinguishable from those seen in MS (Ormerod *et al.*, 1987).

### **Brainstem and spinal cord syndromes**

Acute brainstem disturbance (e.g. vertigo, diplopia) is the presenting feature of MS in approximately 15% of patients, while twice as many will present with spinal cord



Fig. 1.4. Magnetic resonance imaging,  $T_1$  weighted, contrast (gadolinium–DPTA)-enhanced, showing pathological changes in the optic nerve in a patient with multiple sclerosis.

symptoms (sensory, motor and sphincter disturbance).<sup>3</sup> The percentage that go on to develop MS is similar to that with optic neuritis (Miller *et al.*, 1992; Brex *et al.*, 2002).

### The significance of magnetic resonance abnormalities in patients with clinically isolated syndromes

The presence of brain lesions at index presentation is associated with a high risk of progression to MS. Brex *et al.* (2002), followed a group of 71 patients with CIS for 14 years from symptom onset. Of the 50 patients who had brain lesions to begin with, 44 (88%) had progressed to MS. In addition, a further four (8%) patients with an abnormal index MRI had developed clinically probable MS. Of the remaining two patients, one had new lesions on MRI and the other declined follow-up. Therefore, 49 of 50 patients had clinical and/or radiological evidence at follow-up that was compatible with a diagnosis of MS. This contrasts with the findings from the 21 patients whose initial MRI was normal. Here, only four (19%) patients had gone on to develop MS 14 years later.

Data from patients with CIS can predict not only conversion to MS, but also the level of disability associated with it. For example, an Expanded Disability Status

<sup>3</sup> The reader is directed to Polman *et al.* (2005) for a more detailed account of what constitutes MS-related spinal cord pathology.

Score (EDSS) (see below) at 14 years after disease onset correlated reasonably ( $r = 0.60$ ) with lesion volume at the five year follow-up mark and with an increase in lesion volume over the first five years ( $r = 0.61$ ). Collating all the data, the following composite suggested a better long-term prognosis: A CIS presentation of optic neuritis or sensory symptoms, a long period to first relapse, no MRI brain lesions at symptom onset, a small lesion change over the first five years of disease and no disability after five years (Miller *et al.*, 2005).

Of note is that the Poser and McDonald criteria have been compared in a follow-up study of 95 patients with a CIS (Dalton *et al.*, 2002). All subjects underwent a clinical and MRI assessment at baseline and thereafter at three months, one year and three years. The two sets of criteria were applied at each stage to assess the frequency with which MS was diagnosed. The McDonald system gave substantially higher diagnostic yields at every stage. The percentages of patients with MS according to the Poser criteria were 7%, 20% and 38%, respectively, while for the McDonald method the figures were 21%, 48% and 58%, respectively. Given the importance of MRI abnormalities in the McDonald schema, the gist of these findings should not be surprising. It is, however, noteworthy that a diagnosis of MS at one year based on MRI criteria had a high sensitivity (83%) and specificity (83%), and a good predictive value (75%), for clinically definite MS at three years.

## **Differential diagnosis**

The broad array and often subtle nature of neurological signs and symptoms that may herald the onset of MS ensures a formidable list of conditions that make up a differential diagnosis (Rolak, 1996). These include somatization disorder (hysteria), postviral demyelination (acute disseminated encephalomyelitis), vasculitis affecting the CNS (either primary or secondary conditions such as lupus erythematosus), retroviral infections such as acquired immunodeficiency syndrome (AIDS), cerebrovascular accidents (stroke), metachromatic leukodystrophy and tumors (metastases, lymphoma).

To the neuropsychiatrist, dealing primarily with the behavioral sequelae of MS, the somatising patient masquerading with MS-like symptoms can present a considerable therapeutic challenge (Aring, 1965). A follow-up of 400 patients referred to neurologists, and subsequently found not to have MS, revealed 14 with primarily psychiatric problems (Murray and Murray, 1984). These patients were more likely to be female, hospital employees or have a friend with MS and to suffer from anxiety, depression and somatization disorder, the latter formerly called hysteria. Conversely, there are patients with MS who may be incorrectly dismissed as “hysterical.” In a defined population of 112 000 Skegg *et al.* (1988) were able to

identify 91 patients with MS (a point prevalence of 0.08%) of whom 16% had been referred to a psychiatrist between the onset of neurological symptoms and the diagnosis of MS. Although neurological symptoms were present at the time in the majority of patients, these had been overlooked by the psychiatrist in all but two patients. Instead, patients were given diagnoses such as hysterical personality disorder or conversion disorder.

## **The clinical course and severity of multiple sclerosis**

Clear definitions of disease course are essential for a number of reasons. They are now needed by clinicians before they can assign treatment to patients. From a research perspective they help to frame and interpret all clinical and laboratory data. Historically, the problems encountered in defining terms that describe the course and severity of MS (Whitaker *et al.*, 1995) have stemmed from a reliance on verbal descriptors as opposed to biological markers. This recognition led to an international survey of MS researchers with the aim of assessing agreement pertaining to the various descriptive terms currently in use (Lublin and Reingold, 1996). The survey supplied definitions of the following disease courses and types: relapsing–remitting (RR), relapsing–progressive (RP), primary progressive (PP), secondary progressive (SP), benign and malignant. Definitions of each of these terms were included in the survey, but space was also made available for researchers to provide their own definitions if they disagreed with those enclosed. Of the 215 surveys mailed out, 125 (58%) responded. The results led to the National Multiple Sclerosis Society (USA) providing a set of consensus definitions, which are given below.

### **Clinical course definitions**

#### **Relapsing–remitting (RR)**

The consensus definition of RR refers to clearly defined disease relapses with full recovery or with sequelae and residual deficit upon recovery; the periods between disease relapses are characterized by a lack of disease progression. The defining characteristic of this course is the acute episodes of neurological deterioration with variable recovery but a stable course between attacks (Fig. 1.5).

#### **Primary progressive (PP)**

The consensus definition of PP refers to disease progression from symptom onset with occasional plateaus and temporary minor improvements allowed. The cardinal feature here is a gradual, nearly continuous worsening of neurological function from the first presentation, with some minor fluctuations but no discrete relapses (Fig. 1.6).




Fig. 1.5. Relapsing–remitting multiple sclerosis is characterized by (a) clearly defined attacks with complete recovery and (b) sequelae and residual deficit upon recovery. (From Lublin and Reingold [1996] by permission of the American Academy of Neurology.)

### Secondary progressive (SP)

The course of SP is defined as initially RR followed by a progression, with or without occasional relapses, minor remissions and plateaus. SP is viewed as the long-term outcome of patients who initially show a RR course. What characterizes the switch from one to the other is when the baseline between relapses begins to worsen (Fig. 1.7).

### Relapsing–progressive (RP)

There was no consensus amongst those surveyed, largely because of the overlap between the RP term and some of the other categories. The recommendation was for the term to be abandoned.




Fig. 1.6. Primary progressive multiple sclerosis is characterized by disease progression from symptom onset that is either (a) continual or (b) with some occasional plateaux and temporary minor improvements but no discrete relapses. (From Lublin and Reingold [1996] by permission of the American Academy of Neurology.)

### Progressive-relapsing (PR)

The generally agreed definition of PR MS was of progressive disease from symptom onset, with clear, acute relapses, with or without full recovery; the periods between relapses were marked by continuing disease progression. This was considered an additional but rare clinical course that warranted a separate definition (Fig. 1.8).

### Clinical severity definitions

The merits of defining severity according to two terms, “benign” or “malignant,” were surveyed and the results indicated a lack of uniformity amongst researchers. The disagreement was greater for what constituted benign than for malignant